Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
PR Newswire —
-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates -- SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage...